Ibrutinib Capsules 140mg
IBRULIEVA 140 MG (Ibrutinib Capsules 140 mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Ibrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down and control the growth of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists for the management of chronic blood-related malignancies and advanced lymphoma conditions.
Ibrutinib works by targeting specific proteins responsible for the growth and survival of cancer cells. By blocking BTK activity, the medicine interferes with cancer cell signaling pathways and helps reduce the spread of abnormal B-cells. Due to its targeted mechanism of action, IBRULIEVA 140 MG has become an important medicine in modern hematology-oncology treatment protocols.
This targeted therapy capsule is widely used in the treatment of:
• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Waldenström Macroglobulinemia (WM)
• Marginal Zone Lymphoma (MZL)
• Chronic Graft Versus Host Disease (cGVHD)
Doctors may prescribe IBRULIEVA alone or in combination with other oncology medicines depending on the patient’s medical condition, stage of cancer, treatment history, and response to therapy.
IBRULIEVA 140 MG is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine is intended strictly for medical use and should only be taken under the supervision of qualified healthcare professionals.
Blood cancers and lymphatic malignancies can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted cancer therapies like Ibrutinib help improve disease management by specifically targeting cancer-related pathways without affecting healthy cells as extensively as traditional chemotherapy.
Patients receiving IBRULIEVA 140 MG may require regular blood tests, medical monitoring, and health assessments during treatment to help manage side effects and improve treatment outcomes. Doctors carefully determine dosage and treatment duration based on the patient’s overall condition and treatment goals.
Due to its effectiveness in targeted cancer treatment and hematology care, IBRULIEVA 140 MG is widely used in hospitals, oncology centers, hematology clinics, and advanced cancer treatment programs.
View Details
Melphalan Tablet IP 2mg
MELIEVA 2 MG (Melphalan Tablet IP 2 mg) is an anticancer chemotherapy medicine used in the treatment and management of multiple myeloma, ovarian cancer, and certain other cancer-related conditions. It contains Melphalan, a well-known alkylating agent that helps destroy cancer cells by interfering with their DNA and preventing them from multiplying inside the body.
Melphalan is widely used in oncology and hematology treatment programs because of its effectiveness in slowing the growth and spread of abnormal cancer cells. This medicine is commonly prescribed by oncologists as part of chemotherapy treatment protocols for patients requiring long-term cancer management and supportive oncology care.
Cancer cells grow and divide rapidly, affecting normal body functions and overall health. MELIEVA 2 MG works by damaging the genetic material of cancer cells, which reduces their ability to survive and reproduce. This targeted effect helps control cancer progression and supports modern chemotherapy treatment strategies.
MELIEVA 2 MG is mainly used in:
• Multiple myeloma treatment
• Ovarian cancer management
• Bone marrow-related cancer conditions
• Advanced oncology treatment programs
• Certain hematological disorders under specialist supervision
This anticancer medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology treatment.
Doctors may prescribe MELIEVA alone or in combination with other chemotherapy medicines depending on the patient’s medical condition, cancer type, stage of disease, and response to therapy.
Patients receiving Melphalan therapy may require regular blood tests, bone marrow monitoring, liver function assessments, and medical evaluations during treatment. Chemotherapy medicines can affect healthy cells along with cancer cells, so close medical supervision is important for improving treatment outcomes and reducing complications.
Due to its effectiveness in oncology and hematology care, MELIEVA 2 MG has become an important medicine in cancer treatment protocols and long-term chemotherapy management programs.
View Details
Aprepitant Capsules IP 125mg
APRELIEVA 125 MG (Aprepitant Capsules IP 125 mg) is an antiemetic medicine used to help prevent nausea and vomiting caused by chemotherapy treatment and certain medical procedures. It contains Aprepitant, a neurokinin-1 (NK1) receptor antagonist that works by blocking specific signals in the brain responsible for triggering nausea and vomiting.
Cancer patients undergoing chemotherapy often experience severe nausea and vomiting as side effects of anticancer treatment. These symptoms can affect overall health, appetite, energy levels, and quality of life. APRELIEVA 125 MG is specially formulated to help reduce chemotherapy-induced nausea and vomiting (CINV), making cancer treatment more manageable and comfortable for patients.
Aprepitant works differently from traditional anti-nausea medicines. It targets substance P, a natural chemical in the brain associated with the vomiting reflex. By blocking NK1 receptors, APRELIEVA helps prevent both acute and delayed nausea and vomiting that may occur during or after chemotherapy sessions.
This medicine is commonly prescribed along with other antiemetic medicines such as:
• Ondansetron
• Dexamethasone
• Other supportive cancer care medicines
APRELIEVA 125 MG is widely used in:
• Chemotherapy-induced nausea prevention
• Delayed vomiting prevention after chemotherapy
• Supportive oncology care
• Cancer treatment management programs
• Certain surgery-related nausea prevention protocols under medical supervision
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. APRELIEVA should only be used under the guidance of qualified healthcare professionals.
Doctors may prescribe this medicine before chemotherapy sessions to help improve patient comfort and treatment tolerance. Effective nausea management is important because uncontrolled vomiting may lead to dehydration, weakness, nutritional problems, and difficulty continuing cancer treatment.
Patients using APRELIEVA 125 MG may require individualized dosing schedules depending on the type of chemotherapy, severity of symptoms, and overall treatment plan. Proper medical supervision helps improve treatment effectiveness and reduce complications.
Due to its effectiveness in supportive oncology care and chemotherapy-related symptom management, APRELIEVA 125 MG has become an important medicine in modern cancer care protocols.
View Details
Acalabrutinib Capsules 100mg
ACALIEVA 100MG (Acalabrutinib Capsules 100mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Acalabrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down the growth and spread of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists as part of advanced cancer treatment protocols for chronic blood-related malignancies.
Acalabrutinib works by blocking the activity of BTK proteins that are involved in the growth and survival of cancerous B-cells. By interrupting these cancer cell signaling pathways, ACALIEVA 100MG helps reduce the multiplication and survival of abnormal cells, supporting long-term cancer management and disease control.
This targeted therapy medicine is widely used in modern hematology-oncology treatment because of its precision-based mechanism and effectiveness in managing blood cancers with fewer effects on healthy cells compared to some traditional chemotherapy medicines.
ACALIEVA 100MG is mainly prescribed for the treatment of:
• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Certain relapsed or refractory blood cancers
• Advanced hematology-oncology treatment programs
Doctors may prescribe Acalabrutinib Capsules alone or in combination with other anticancer medicines depending on the patient’s condition, stage of disease, previous treatment history, and response to therapy.
Blood cancers can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted therapy medicines like Acalabrutinib help control cancer progression by specifically targeting cancer-related proteins responsible for abnormal B-cell growth.
ACALIEVA 100MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and reliable therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology treatment.
Patients undergoing treatment with ACALIEVA may require regular blood tests, medical monitoring, infection screening, and overall health assessments during therapy. Proper monitoring helps improve treatment effectiveness and reduce the risk of complications or serious side effects.
Due to its effectiveness in targeted cancer therapy and hematology care, ACALIEVA 100MG has become an important medicine in modern oncology treatment protocols and long-term blood cancer management programs.
View Details
Erlotinib Tablets IP 150mg
ERLOLIEVA 150 MG (Erlotinib Tablets IP 150mg) is a targeted anticancer medicine used in the treatment of certain types of lung cancer and pancreatic cancer. It contains Erlotinib Hydrochloride, a highly effective Epidermal Growth Factor Receptor (EGFR) inhibitor that helps slow down the growth and spread of cancer cells in the body. This medicine is commonly prescribed by oncologists as part of modern targeted cancer therapy protocols for patients with specific cancer types and genetic profiles.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. In some cancers, proteins known as Epidermal Growth Factor Receptors (EGFR) play an important role in helping cancer cells survive, multiply, and spread. ERLOLIEVA 150 MG works by blocking these receptors, thereby interfering with cancer cell growth and reducing tumor progression.
Unlike traditional chemotherapy, Erlotinib is a targeted therapy that focuses on specific pathways involved in cancer development. This targeted approach helps improve treatment effectiveness in eligible patients while minimizing damage to healthy cells. As a result, Erlotinib has become an important treatment option in oncology care, especially for patients with EGFR-positive cancers.
ERLOLIEVA 150 MG is commonly prescribed for:
• Non-Small Cell Lung Cancer (NSCLC)
• EGFR Mutation-Positive Lung Cancer
• Advanced or Metastatic Lung Cancer
• Pancreatic Cancer (in combination with other treatments)
• Long-term targeted oncology treatment programs
This medicine may be used as a first-line treatment or after other cancer therapies depending on the patient's condition, treatment history, and medical requirements.
ERLOLIEVA 150 MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and consistent therapeutic performance. It is intended strictly for use under the supervision of qualified healthcare professionals experienced in oncology treatment.
Patients receiving Erlotinib therapy may require regular medical monitoring, blood tests, liver function assessments, and imaging studies during treatment. Proper monitoring helps evaluate treatment response and manage potential side effects effectively.
Due to its effectiveness in targeted oncology therapy, ERLOLIEVA 150 MG has become an important medicine in modern cancer care and personalized treatment programs.
View Details
Lapatinib Tablets 250 mg
LAPALIEVA 250 MG (Lapatinib Tablets 250 mg) is a targeted anticancer medicine used in the treatment of certain types of HER2-positive breast cancer. It contains Lapatinib, an advanced tyrosine kinase inhibitor (TKI) that works by blocking specific proteins responsible for the growth and spread of cancer cells. This targeted therapy is widely prescribed by oncologists for patients with advanced, metastatic, or treatment-resistant breast cancer.
Breast cancer remains one of the most commonly diagnosed cancers worldwide. In some patients, cancer cells produce excessive amounts of a protein known as Human Epidermal Growth Factor Receptor 2 (HER2). This protein promotes rapid cancer cell growth and increases the aggressiveness of the disease. LAPALIEVA 250 MG helps control this process by targeting HER2 and Epidermal Growth Factor Receptor (EGFR), thereby slowing cancer progression and supporting long-term disease management.
Unlike traditional chemotherapy, Lapatinib specifically targets cancer-related pathways, making it an important component of modern precision oncology treatment. It is often used in combination with other anticancer medicines to improve treatment outcomes and help patients achieve better disease control.
LAPALIEVA 250 MG is commonly prescribed for:
• HER2-positive metastatic breast cancer
• Advanced breast cancer
• Hormone receptor-positive and HER2-positive breast cancer
• Recurrent breast cancer
• Combination targeted therapy protocols
• Long-term oncology treatment programs
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, efficacy, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and cancer treatment.
Patients receiving LAPALIEVA 250 MG may require regular medical monitoring, imaging studies, liver function assessments, and cardiac evaluations throughout therapy. These assessments help doctors evaluate treatment effectiveness and identify any potential complications early.
Because of its proven effectiveness in HER2-positive breast cancer treatment, LAPALIEVA 250 MG has become an important part of modern targeted cancer therapy and personalized oncology care.
View Details
Sorafenib Tablets 200mg
SORALIEVA 200MG (Sorafenib Tablets 200mg) is a targeted anticancer medicine used in the treatment of specific types of liver cancer, kidney cancer, and thyroid cancer. It contains Sorafenib Tosylate, a multikinase inhibitor that helps slow the growth and spread of cancer cells by blocking certain proteins and signaling pathways involved in tumor development and blood vessel formation.
Cancer cells require a constant supply of nutrients and oxygen to grow and spread. Sorafenib works by targeting multiple kinases involved in cancer cell proliferation and angiogenesis (the formation of new blood vessels that feed tumors). By blocking these pathways, SORALIEVA 200MG helps reduce tumor growth and may slow disease progression in eligible patients.
Unlike conventional chemotherapy, Sorafenib is a targeted therapy designed to interfere with specific molecular mechanisms that support cancer growth. This approach makes it an important treatment option in modern oncology, especially for patients with advanced or metastatic cancers.
SORALIEVA 200MG is commonly prescribed for:
• Hepatocellular Carcinoma (HCC) – Liver Cancer
• Advanced Renal Cell Carcinoma (RCC) – Kidney Cancer
• Differentiated Thyroid Carcinoma (DTC)
• Advanced or Metastatic Solid Tumors
• Long-Term Targeted Cancer Therapy Programs
The medicine is often recommended when surgery or other treatment options are not suitable, or when cancer has progressed despite previous therapies.
Manufactured under stringent pharmaceutical quality standards, SORALIEVA 200MG is designed to provide reliable therapeutic performance and consistent quality. It should only be used under the supervision of qualified oncologists or healthcare professionals experienced in cancer treatment.
Patients undergoing treatment with Sorafenib may require regular blood tests, liver function monitoring, blood pressure assessments, and imaging studies to evaluate treatment effectiveness and manage potential side effects.
Due to its effectiveness in advanced cancer management, SORALIEVA 200MG has become an important component of modern targeted oncology treatment protocols worldwide.
View Details
Axitinib Tablets 5 mg
AXILIEVA 5MG (Axitinib Tablets 5 mg) is a targeted anticancer medicine used in the treatment of advanced kidney cancer (Renal Cell Carcinoma) and certain other oncology indications as prescribed by healthcare professionals. It contains Axitinib, a potent vascular endothelial growth factor receptor (VEGFR) inhibitor that helps slow the growth and spread of cancer cells by reducing the formation of new blood vessels that tumors need to survive and grow.
Cancer cells depend on a steady blood supply to receive oxygen and nutrients. Axitinib works by blocking specific receptors involved in angiogenesis, the process through which tumors create new blood vessels. By inhibiting these pathways, AXILIEVA 5MG helps restrict tumor growth and may contribute to better disease control in eligible patients.
Unlike conventional chemotherapy, Axitinib is a targeted therapy that focuses on molecular pathways associated with cancer progression. This precision-based approach allows oncologists to manage certain cancers more effectively while supporting individualized treatment strategies.
AXILIEVA 5MG is commonly prescribed for:
• Advanced Renal Cell Carcinoma (RCC)
• Metastatic Kidney Cancer
• Targeted Oncology Treatment Programs
• Combination Immunotherapy Protocols
• Long-Term Cancer Management
• Advanced Solid Tumor Treatment Under Specialist Guidance
The medicine may be used alone or in combination with other anticancer therapies depending on the patient’s diagnosis, treatment history, and overall health condition.
Manufactured under stringent pharmaceutical quality standards, AXILIEVA 5MG is designed to deliver reliable therapeutic performance and consistent product quality. The medicine should only be used under the supervision of qualified oncologists and healthcare professionals experienced in cancer treatment.
Patients receiving Axitinib therapy may require regular monitoring of blood pressure, liver function, kidney function, thyroid function, and overall treatment response. These evaluations help optimize treatment outcomes and manage potential side effects effectively.
Due to its effectiveness in targeted oncology care, AXILIEVA 5MG has become an important component of modern kidney cancer treatment protocols and precision cancer therapy programs.
View Details
Hydroxyurea Capsules IP 500mg
HYDLIEVA 500MG (Hydroxyurea Capsules IP 500mg) is a prescription medicine used in the treatment of certain blood disorders and cancers. It contains Hydroxyurea 500mg, a well-established antimetabolite medication that works by slowing the growth and multiplication of abnormal cells in the body. Hydroxyurea is widely prescribed by hematologists and oncologists for managing conditions such as chronic myeloid leukemia, sickle cell disease, and other myeloproliferative disorders.
HYDLIEVA 500MG plays an important role in modern hematology and oncology treatment because it helps control excessive blood cell production and reduces disease-related complications. The medicine works by interfering with DNA synthesis, which slows down the growth of rapidly dividing cells. This mechanism makes Hydroxyurea effective in managing both cancerous and non-cancerous blood disorders.
Patients with blood-related conditions often require long-term treatment and careful monitoring. HYDLIEVA 500MG helps improve disease control, reduce complications, and support overall quality of life when used under appropriate medical supervision.
This medicine is commonly prescribed for:
• Chronic Myeloid Leukemia (CML)
• Sickle Cell Disease
• Polycythemia Vera
• Essential Thrombocythemia
• Certain Myeloproliferative Disorders
• Blood Cell Production Disorders
• Hematology and Oncology Treatment Programs
Hydroxyurea has been widely used for many years and remains an important treatment option in specialized blood disorder management. It is particularly valuable in sickle cell disease, where it helps reduce painful crises and improve overall disease outcomes.
HYDLIEVA 500MG is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals.
Patients receiving Hydroxyurea therapy may require regular blood tests, kidney function monitoring, liver function assessments, and medical evaluations throughout treatment. These assessments help ensure treatment effectiveness and identify potential side effects early.
Due to its proven effectiveness in hematology and oncology care, HYDLIEVA 500MG remains an important medicine in modern blood disorder treatment programs.
View Details
Bicalutamide Tablet IP 50mg
BICALIEVA 50MG (Bicalutamide Tablet IP 50mg) is a prescription anti-cancer medicine used in the treatment and management of prostate cancer. It contains Bicalutamide 50mg, a non-steroidal antiandrogen that works by blocking the effects of male hormones (androgens), particularly testosterone, which can stimulate the growth of prostate cancer cells.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells rely on testosterone and other androgens to grow and multiply. BICALIEVA 50MG helps control the disease by preventing these hormones from attaching to cancer cells, thereby slowing cancer growth and reducing tumor progression.
Bicalutamide is widely used as part of hormone therapy for prostate cancer and is often prescribed in combination with other treatments such as luteinizing hormone-releasing hormone (LHRH) agonists or surgical castration. This combined approach helps achieve more effective androgen deprivation, which is an important strategy in prostate cancer management.
BICALIEVA 50MG is commonly prescribed for:
• Advanced Prostate Cancer
• Metastatic Prostate Cancer
• Hormone-Sensitive Prostate Cancer
• Androgen Deprivation Therapy (ADT)
• Combination Prostate Cancer Treatment
• Long-Term Oncology and Urology Care
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and urology treatment.
Patients receiving BICALIEVA 50MG may require regular monitoring of prostate-specific antigen (PSA) levels, liver function, overall treatment response, and routine medical evaluations. These assessments help healthcare providers optimize treatment outcomes and manage potential side effects effectively.
Due to its proven role in hormone-based prostate cancer treatment, BICALIEVA 50MG remains an important medicine in modern oncology and urology care programs.
View Details
Letrozole Tablets IP 2.5 mg
LETROLIEVA 2.5 MG (Letrozole Tablets IP 2.5 mg) is a prescription medicine used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It contains Letrozole 2.5 mg, a highly effective aromatase inhibitor that helps reduce estrogen levels in the body. Since certain breast cancers depend on estrogen for growth and survival, lowering estrogen levels can help slow or stop the growth of cancer cells.
Breast cancer is one of the most common cancers affecting women worldwide. In many cases, cancer cells possess hormone receptors that respond to estrogen. LETROLIEVA 2.5 MG works by blocking the aromatase enzyme, which is responsible for producing estrogen in postmenopausal women. By reducing estrogen production, the medicine helps prevent cancer cells from receiving the hormonal stimulation they need to grow.
Letrozole is widely used as part of modern hormone therapy and targeted breast cancer treatment programs. It may be prescribed after surgery, radiation therapy, chemotherapy, or as a long-term maintenance treatment to reduce the risk of cancer recurrence.
LETROLIEVA 2.5 MG is commonly prescribed for:
• Hormone Receptor-Positive Breast Cancer
• Early-Stage Breast Cancer
• Advanced Breast Cancer
• Metastatic Breast Cancer
• Adjuvant Hormonal Therapy
• Long-Term Breast Cancer Management
• Postmenopausal Breast Cancer Treatment
In addition to its role in oncology, Letrozole may sometimes be prescribed for fertility-related conditions under specialist supervision. However, its primary use remains breast cancer treatment and management.
Manufactured under stringent pharmaceutical quality standards, LETROLIEVA 2.5 MG is designed to provide consistent therapeutic performance and reliable treatment outcomes. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hormone therapy.
Patients receiving Letrozole therapy may require regular medical monitoring, bone density assessments, cholesterol evaluations, and routine follow-up visits to ensure safe and effective treatment.
Due to its proven effectiveness in reducing breast cancer recurrence and supporting long-term disease control, LETROLIEVA 2.5 MG has become an essential medicine in modern breast cancer care.
View Details
Anastrozole Tablets 1 mg
ANALIEVA 1 MG (Anastrozole Tablets 1 mg) is a prescription hormone therapy medicine used for the treatment and management of hormone receptor-positive breast cancer in postmenopausal women. It contains Anastrozole 1 mg, a highly effective aromatase inhibitor that helps reduce estrogen production in the body. Since many breast cancers depend on estrogen to grow and spread, lowering estrogen levels can help slow cancer progression and reduce the risk of recurrence.
Breast cancer is one of the most common cancers affecting women globally. In hormone receptor-positive breast cancer, cancer cells use estrogen as a growth signal. ANALIEVA 1 MG works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogen in postmenopausal women. By significantly reducing estrogen levels, the medicine helps prevent cancer cells from receiving the hormonal stimulation they need to survive and multiply.
Anastrozole has become an important part of modern breast cancer treatment protocols and is widely recommended by oncologists for both early-stage and advanced hormone-sensitive breast cancer. It is often prescribed after surgery, radiation therapy, or chemotherapy to support long-term disease control and improve treatment outcomes.
ANALIEVA 1 MG is commonly prescribed for:
• Hormone Receptor-Positive Breast Cancer
• Early-Stage Breast Cancer
• Advanced Breast Cancer
• Metastatic Breast Cancer
• Adjuvant Hormonal Therapy
• Long-Term Breast Cancer Management
• Postmenopausal Breast Cancer Treatment
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, efficacy, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and hormonal cancer therapy.
Patients receiving ANALIEVA 1 MG may require regular medical monitoring, bone density assessments, cholesterol evaluations, and routine follow-up visits to ensure treatment effectiveness and manage potential side effects.
Due to its proven effectiveness in reducing breast cancer recurrence and supporting long-term disease management, ANALIEVA 1 MG remains an essential medicine in modern breast cancer care.
View Details
